Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity.
Saved in:
| Title: | Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity. |
|---|---|
| Authors: | Ozberk U; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Esen SA, Sekmek S, Seven I, Bal O, Algin E, Yucel S, Uncu D |
| Source: | Anti-cancer drugs [Anticancer Drugs] 2026 Jul 01; Vol. 37 (6), pp. 359-365. Date of Electronic Publication: 2026 May 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41430637 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ozberk+U%22">Ozberk U</searchLink>; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Esen+SA%22">Esen SA</searchLink><br /><searchLink fieldCode="AU" term="%22Sekmek+S%22">Sekmek S</searchLink><br /><searchLink fieldCode="AU" term="%22Seven+I%22">Seven I</searchLink><br /><searchLink fieldCode="AU" term="%22Bal+O%22">Bal O</searchLink><br /><searchLink fieldCode="AU" term="%22Algin+E%22">Algin E</searchLink><br /><searchLink fieldCode="AU" term="%22Yucel+S%22">Yucel S</searchLink><br /><searchLink fieldCode="AU" term="%22Uncu+D%22">Uncu D</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229100823%22">Anti-cancer drugs</searchLink> [Anticancer Drugs] 2026 Jul 01; Vol. 37 (6), pp. 359-365. <i>Date of Electronic Publication: </i>2026 May 06. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lippincott+Williams+%26+Wilkins%22">Lippincott Williams & Wilkins </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9100823 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1473-5741 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209594973%22">09594973 </searchLink><i>NLM ISO Abbreviation: </i>Anticancer Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41430637 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1097/CAD.0000000000001798 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 359 Titles: – TitleFull: Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ozberk U – PersonEntity: Name: NameFull: Esen SA – PersonEntity: Name: NameFull: Sekmek S – PersonEntity: Name: NameFull: Seven I – PersonEntity: Name: NameFull: Bal O – PersonEntity: Name: NameFull: Algin E – PersonEntity: Name: NameFull: Yucel S – PersonEntity: Name: NameFull: Uncu D IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2026 Jul 01 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1473-5741 Numbering: – Type: volume Value: 37 – Type: issue Value: 6 Titles: – TitleFull: Anti-cancer drugs Type: main |
| ResultId | 1 |
